It was approved by the U.S. Food and Drug Administration (FDA) for this indication on 15 December 2008.[11] In the European Union, the drug was approved after a positive Committee for Medicinal Products for Human Use assessment report on 29 May 2009.[2] The drug was approved for use in Canada by Health Canada on 8 December 2011.[12]